<DOC>
	<DOCNO>NCT00066781</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine irinotecan use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together irinotecan work treat patient cancer unknown primary origin .</brief_summary>
	<brief_title>Gemcitabine Irinotecan Treating Patients With Cancer Unknown Primary</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient carcinoma unknown primary treat gemcitabine irinotecan . - Determine adverse event profile tolerability regimen , base presence absence UGT1A1*28 polymorphism , patient . ( Cohort I close accrual 11/17/05 ) - Determine adverse event profile tolerability regimen . ( Cohort II ) Secondary - Determine time progression overall survival patient treat regimen . - Correlate pattern immunohistochemical stain response patient treat regimen . - Correlate variation multiple different gene , whose protein product involve uptake , metabolism , distribution drug , clinical outcome , term response toxicity , patient . - Determine primary origin cancer unknown primary sample complete 92-gene RT-PCR cancer classification assay . - Determine whether 92-gene assay result correlate clinical response gemcitabine irinotecan . OUTLINE : - Cohort I ( close accrual 11/17/05 ) : Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 , 8 , 15 , 22 . Irinotecan dose may escalate de-escalated course 1 depend toxicity . Courses repeat every 6 week absence disease progression unacceptable toxicity . - Cohort II : Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma undetermined origin , follow light microscopic diagnosis : Adenocarcinoma Poorly differentiate nonsmall cell carcinoma Poorly differentiate squamous cell carcinoma Primary site reveal following diagnostic test : Complete history physical Complete blood count chemistry Chest xray and/or CT scan Abdominal CT scan Directed evaluation symptomatic area Mammogram woman Colonoscopy patient liver metastasis exclude colon primary Hematoxylin eosin ( H &amp; E ) staining OR immunostaining H &amp; E result unclear , include follow : Keratin epithelial membrane antigen S100 HMB45 LCA ( CD45 ) Chromogranin synaptophysin Thyroid transcription factor 1 Measurable disease Patients follow condition eligible : Neuroendocrine tumor Women axillary node involvement Women adenocarcinoma peritoneum Carcinoma involve 1 site , resectable tumor site Squamous cell carcinoma limit cervical , supraclavicular , inguinal lymph node Men poorly differentiate mediastinal retroperitoneal tumor stain suggestive germ cell origin serum tumor marker ( AFP/HCG ) Men prominent blastic bony metastasis markedly elevate prostatespecific antigen , suggest prostate origin Must willing provide blood tissue sample No brain meningeal involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin must meet 1 follow criterion : Less equal upper limit normal ( ULN ) UGT1A1 genotyping require Greater ULN less 2 time ULN UGT1A1 6/7 genotype 7/7 genotype patient Alkaline phosphatase great 3 time ULN AST great 3 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine great 2.0 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 5 year No severe concurrent disease would make patient inappropriate study judgment investigator No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic agent No concurrent filgrastim ( GCSF ) Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery More 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma unknown primary</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
	<keyword>squamous cell carcinoma unknown primary</keyword>
	<keyword>undifferentiated carcinoma unknown primary</keyword>
</DOC>